UK markets close in 3 hours 38 minutes
  • FTSE 100

    7,156.62
    +27.41 (+0.38%)
     
  • FTSE 250

    22,805.50
    +120.66 (+0.53%)
     
  • AIM

    1,192.05
    +3.31 (+0.28%)
     
  • GBP/EUR

    1.1745
    -0.0021 (-0.18%)
     
  • GBP/USD

    1.3279
    -0.0023 (-0.18%)
     
  • BTC-GBP

    42,857.79
    +186.68 (+0.44%)
     
  • CMC Crypto 200

    1,452.46
    +13.58 (+0.94%)
     
  • S&P 500

    4,577.10
    +64.06 (+1.42%)
     
  • DOW

    34,639.79
    +617.75 (+1.82%)
     
  • CRUDE OIL

    68.41
    +1.91 (+2.87%)
     
  • GOLD FUTURES

    1,772.80
    +10.10 (+0.57%)
     
  • NIKKEI 225

    28,029.57
    +276.20 (+1.00%)
     
  • HANG SENG

    23,766.69
    -22.24 (-0.09%)
     
  • DAX

    15,311.81
    +48.70 (+0.32%)
     
  • CAC 40

    6,806.03
    +10.28 (+0.15%)
     

Sernova to Present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum

·3-min read

DGAP-News: Sernova Corp. / Key word(s): Conference
16.11.2021 / 12:05
The issuer is solely responsible for the content of this announcement.

LONDON, ONTARIO, CANADA - November 16, 2021 - Sernova Corp. (TSX-V:SVA)(FSE/XETRA:PSH)(OTCQB:SEOVF), a leading clinical-stage company focused on regenerative medicine therapeutics, today announced that Dr. Philip Toleikis, President and CEO, will present at the Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum on Thursday, November 18th, 2021 at 10:00am ET.

Management will be available throughout the conference for virtual one-on-one meetings. Investors interested in arranging a meeting with the Company's management during the conference should contact the Canaccord Genuity conference coordinator or Sernova investor relations.

Webcast Information:

A live webcast of Sernova's presentation session will be available under 'Featured News' on the Company's website at https://www.sernova.com/press or by accessing the event directly at following link: https://wsw.com/webcast/canaccord61/sva.v/2570694.

ABOUT SERNOVA

Sernova is developing regenerative medicine therapeutic technologies using an implantable medical device and immune protected therapeutic cells (i.e. human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.

FOR FURTHER INFORMATION, PLEASE CONTACT:

Investors:
Corey Davis, Ph.D.
LifeScience Advisors, LLC
cdavis@lifesciadvisors.com
212-915-2577

Corporate:
Sernova Corp.
519-858-5126
investor.relations@sernova.com
www.sernova.com

FORWARD-LOOKING INFORMATION

This release contains statements that, to the extent they are not recitations of historical facts, may constitute "forward-looking statements" that involve various risks, uncertainties, and assumptions, including, without limitation, statements regarding the prospects, plans, and objectives of the company. Wherever possible, but not always, words such as "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential for" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur are used to identify forward-looking statements. These statements reflect management's beliefs with respect to future events, including results of clinical trials, and are based on information currently available to management on the date such statements were made. Many factors could cause Sernova's actual results, performances, or achievements to not be as anticipated, estimated or intended or to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Many of the factors are beyond our control, including those caused by, related to, or impacted by the novel coronavirus pandemic. Investors should consult the company's quarterly and annual filings available on www.sedar.com for additional information on risks and uncertainties relating to the forward-looking statements. Sernova expressly disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


16.11.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

Language:

English

Company:

Sernova Corp.

700 Collip Circle, Ste 114

N6G 4X8 London

Canada

Internet:

https://www.sernova.com/contact/

EQS News ID:

1249323


 

End of News

DGAP News Service

show this
show this
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting